scholarly journals Circular Noncoding RNA NR3C1 Acts as a miR-382-5p Sponge to Protect RPE Functions via Regulating PTEN/AKT/mTOR Signaling Pathway

2020 ◽  
Vol 28 (3) ◽  
pp. 929-945 ◽  
Author(s):  
Xue Chen ◽  
Chao Jiang ◽  
Ruxu Sun ◽  
Daidi Yang ◽  
Qinghuai Liu
Keyword(s):  
Signaling Pathway ◽  
Noncoding Rna ◽  
Mtor Signaling ◽  
Mtor Signaling Pathway

scholarly journals Emerging Role of mTOR Signaling-Related miRNAs in Cardiovascular Diseases

2018 ◽  
Vol 2018 ◽  
pp. 1-23 ◽  
Author(s):  
Arun Samidurai ◽  
Rakesh C. Kukreja ◽  
Anindita Das
Keyword(s):  
Cardiovascular Diseases ◽  
Cardiovascular System ◽  
Signaling Pathway ◽  
Noncoding Rna ◽  
Current Knowledge ◽  
Mammalian Target Of Rapamycin ◽  
Vital Role ◽  
Mtor Signaling ◽  
Cellular Growth ◽  
Mtor Signaling Pathway

Mechanistic/mammalian target of rapamycin (mTOR), an atypical serine/threonine kinase of the phosphoinositide 3-kinase- (PI3K-) related kinase family, elicits a vital role in diverse cellular processes, including cellular growth, proliferation, survival, protein synthesis, autophagy, and metabolism. In the cardiovascular system, the mTOR signaling pathway integrates both intracellular and extracellular signals and serves as a central regulator of both physiological and pathological processes. MicroRNAs (miRs), a class of short noncoding RNA, are an emerging intricate posttranscriptional modulator of critical gene expression for the development and maintenance of homeostasis across a wide array of tissues, including the cardiovascular system. Over the last decade, numerous studies have revealed an interplay between miRNAs and the mTOR signaling circuit in the different cardiovascular pathophysiology, like myocardial infarction, hypertrophy, fibrosis, heart failure, arrhythmia, inflammation, and atherosclerosis. In this review, we provide a comprehensive state of the current knowledge regarding the mechanisms of interactions between the mTOR signaling pathway and miRs. We have also highlighted the latest advances on mTOR-targeted therapy in clinical trials and the new perspective therapeutic strategies with mTOR-targeting miRs in cardiovascular diseases.

scholarly journals HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas

Oncotarget ◽  
2016 ◽  
Vol 7 (12) ◽  
pp. 14429-14440 ◽  
Author(s):  
Yu Zhu ◽  
Xuebin Zhang ◽  
Lisha Qi ◽  
Ying Cai ◽  
Ping Yang ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Long Noncoding Rna ◽  
Rna Silencing ◽  
Noncoding Rna ◽  
Mtor Signaling ◽  
Mtor Signaling Pathway ◽  
Human Gliomas

scholarly journals Long noncoding RNA PICSAR/miR‐588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway

2020 ◽  
Vol 111 (11) ◽  
pp. 4118-4128 ◽  
Author(s):  
Zhikui Liu ◽  
Huanye Mo ◽  
Liankang Sun ◽  
Liang Wang ◽  
Tianxiang Chen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Signaling Pathway ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Mtor Signaling ◽  
Mtor Signaling Pathway

UPF1 Impacts on mTOR Signaling Pathway and Autophagy in Endometrioid Endometrial Carcinoma

2020 ◽  
Author(s):  
Minfen Zhang ◽  
Hui Chen ◽  
Ping Qin ◽  
Tonghui Cai ◽  
Lingjun Li ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Mtor Signaling ◽  
Mtor Signaling Pathway

Targeting mammalian target of rapamycin: prospects for the treatment of inflammatory bowel diseases

2020 ◽  
Vol 27 ◽  
Author(s):  
Naser-Aldin Lashgari ◽  
Nazanin Momeni Roudsari ◽  
Saeideh Momtaz ◽  
Negar Ghanaatian ◽  
Parichehr Kohansal ◽  
...  
Keyword(s):  
Signaling Pathway ◽  
Mammalian Target Of Rapamycin ◽  
Mtor Pathway ◽  
Mtor Signaling ◽  
Target Of Rapamycin ◽  
In Vivo Studies ◽  
Cochrane Library ◽  
Mtor Signaling Pathway ◽  
Inflammatory Bowel

: Inflammatory bowel disease (IBD) is a general term for a group of chronic and progressive disorders. Several cellular and biomolecular pathways are implicated in the pathogenesis of IBD, yet the etiology is unclear. Activation of the mammalian target of rapamycin (mTOR) pathway in the intestinal epithelial cells was also shown to induce inflammation. This review focuses on the inhibition of the mTOR signaling pathway and its potential application in treating IBD. We also provide an overview on plant-derived compounds that are beneficial for the IBD management through modulation of the mTOR pathway. Data were extracted from clinical, in vitro and in vivo studies published in English between 1995 and May 2019, which were collected from PubMed, Google Scholar, Scopus and Cochrane library databases. Results of various studies implied that inhibition of the mTOR signaling pathway downregulates the inflammatory processes and cytokines involved in IBD. In this context, a number of natural products might reverse the pathological features of the disease. Furthermore, mTOR provides a novel drug target for IBD. Comprehensive clinical studies are required to confirm the efficacy of mTOR inhibitors in treating IBD.

Sign in / Sign up

Export Citation Format

Share Document